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The influence of pre-operative
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hypospadias repair
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Androgen stimulation to temporarily promote penile growth has been commonly used
to facilitate hypospadias repair. Although some series suggest improvement in both
functional and cosmetic outcomes, a recent systematic review andmeta-analysis showed
a possible relationship between pre-operative hormonal stimulation and higher compli-
cations. As a result, indications and treatment regimens remain controversial. Here, we
review the available literature and present our clinical practice.
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Background
Hypospadias is the second most common male genital birth defect with an incidence of 1 in every
250 male births. Boys with proximal hypospadias typically have small glans penis, making hypospa-
dias repair a technically demanding operation. Repair requires availability of tissue to reconstruct
a neourethra of adequate caliber to allow low pressure voiding while minimizing complications
including glans dehiscence, urethrocutaneous fistula, meatal stenosis, and unsatisfactory cosmesis
secondary to penile scarring. To improve outcomes, use of pre-operative hormonal stimulation
(PHS) prior to surgery has been accepted as a relatively common practice among pediatric urologists
and surgeons for decades despite the lack of high quality evidence to support it.
Hypoplasia of the penis is believed to make repair more challenging, leading to poorer functional
and cosmetic results. Histological studies show that androgens increase the number and density of
blood vessels, supporting a theory of neovascularization (1). Observational studies have shown that
testosterone (T), dihydrotestosterone (DHT), and human chorionic gonadotropin (hCG) have been
associated with a temporary increase in penile length, glans circumference, and tissue vascularity
(2–4). These changes have been hypothesized to improve outcomes of hypospadias repair.
Despite widespread use, PHS has been scarcely reported within the literature and outcomes
remain controversial. Basic science studies show that androgens impair wound healing and promote
inflammation (5). There is also some evidence of potential adverse effects including pubic hair
growth, aggressive behavior, accelerated linear height, and bone age. Due to the paucity of high qual-
ity evidence, standardized protocols and guidelines are lacking. Herein, we reviewed the currently
available literature regarding PHS and present our clinical practice from a tertiary pediatric hospital.
Surgical Outcomes
Data regarding PHS are mostly from non-randomized studies with limited sample sizes. Koff and
Jayanthi reported that hCG significantly increased penile growth, particularly in the proximal region,
and moved the meatus closer toward the tip of the glans. They also showed that hCG thickened the
corpus spongiosum and decreased chordee severity (6).
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In the only randomized controlled trial of 75 consecutive
boys, transdermal DHT was shown to decrease complications
and improve cosmetic results, including a reduction of penile
curvature (7). However, most boys included in this study hadmild
hypospadias, with 70% of the meatus located at the corona, 24%
at the penile shaft, and only 5% at the penoscrotal junction.
On the other hand, a non-randomized cohort study byGorduza
et al. of 126 boys, of whom 30 received PHS, showed that healing
complications were higher in the PHS cohort (30%) compared to
the non-PHS cohort (17.7%) (p= 0.23) (8). This was a small series
to reach statistical significance and there was considerable hetero-
geneity regarding the patients and treatment regimen. Androgen
stimulation was also used in more severe cases of hypospadias
(penile length <25mm, hypoplasia and associated undescended
testes), which one would expect higher complications regardless
of PHS use.
Systematic Review and Meta-Analysis
In a recent systematic review and meta-analysis by Wright et al.
summarizing the effect of PHS on overall complications, a total
of 622 patients were included, of whom 283 (45%) received some
form of PHS (9). Of the 11 included studies, most were retro-
spective observational studies of low or moderate methodological
quality. Four studies that addressed post-operative complication
rates stratified by PHS were included in a meta-analysis that
suggested a possible relationship between PHS and increased
complication rates in boys with severe hypospadias defects with
a non-significant odds ratio of 1.67 (p= 0.07).
This finding, however, may have been a result of selection bias
within the incorporated studies. Given the subjectivity involved
in choosing patients for PHS, it is possible that those selected
had more severe anatomical defects with unfavorable tissue char-
acteristic, and consequently carried a greater complication risk.
In addition, there was considerable variation and heterogene-
ity regarding treatment regimen, confounding the results and
making them difficult to apply to clinical practice. Another
systematic review of 14 studies was performed, including 3
randomized non-blinded studies and 11 non-randomized, non-
placebo controlled studies. Similarly, the authors also concluded
that the real benefit of PHS on surgical results has yet to be
defined (10).
These systematic reviews highlighted that the published litera-
ture in this topic is limited and generally of low quality with lack of
standardized reporting of important patient and surgical details.
Future studies should not only report treatment regimes and
technical details, but should also aim to stratify patients according
to hypospadias severity, preferably in an objective fashion.
Indications
Although use of PHS is relatively common, reported indications
within the literature are quite subjective and at times lacking.
Androgens are typically given in severe cases of hypospadias
with the meatus located proximal to the penile mid shaft or
with proximal division of the corpus spongiosum (11). Other
common indications in the literature include penile length
<25mm, microphallic penile hypoplasia, associated UDT, and
reoperations (9). Boys treated with PHS vary in severity from
those with meatal location at the distal penile shaft to the per-
ineum. However, there are no clear guidelines available regarding
when to use PHS.
A recent study that characterized the practice patterns among
mainly North American pediatric urologists via email-based sur-
veys showed that 78% use PHS (12). Androgens were prescribed
primarily in small appearing penis, reduced glans circumference,
reduced urethral plate width, or proximal hypospadias. However,
treatment regimens and definite indications were highly variable.
Treatment Regimens
Androgen type, deliverymode, dosage, scheduling, and time from
PHS to operation are poorly reported in the literature and there
is no consensus regarding the details of PHS with lack of data
to support one regimen over another. Table 1 summarizes the
relevant literature and various hormone regimens. This paucity
limits our ability to clearly evaluate various treatment protocols.
Type
Several types of PHS are available, with the majority of studies
using T compared to DHT and hCG. In a systematic review,
10 studies used T, 2 DHT, 3 hCG, and 1 LH releasing hormone
and hCG (10). Some authors feel that DHTmay be more effective
as it does not rely on 5-alpha reductase activity for conversion of
T to DHT. The use of certain PHS varies further depending on
geographical availability. Unfortunately, there are no randomized
studies in the literature directly comparing T to DHT or hCG to
support the use of agent over another.
Delivery Mode
Androgen stimulation may be administered via various routes
including topically and intramuscularly. While T, DHT, and hCG
are commonly administered by the intramuscular route, DHT
and T may be given topically and are found to provide high
concentrations. In contrast to the topical route, which is asso-
ciated with variations in serum T levels, the systemic routes
allows for more reliable serum levels (21–23). Topical use also
demands parental compliance for the child to receive appropriate
dosages (22). Regardless, randomized studies directly comparing
topical and intramuscular androgen administration do not show
any differences in penile growth between the routes (4, 21). In
the systematic review, intramuscular administration seemed to
have fewer adverse events than topical (10). In particular, it was
noted that topical administration was associated with more skin
irritation and genital pigmentation.
Dosage and Schedule
Typical doses and scheduling of androgens vary within the litera-
ture. Some authors use intramuscular T doses adapted to patient’s
size with substantial effects on penile growth by using doses of
2mg/kg/dose for two to three doses (2, 15, 19, 24) or 100mg/m2
(8, 18). Alternatively, fixed doses of T at 25mg/dose IM once
monthly for 3months have also been used with no significant
adverse effects such as delay in bone age (11, 14). Similar effects
can be achieved with topical 10% T propionate cream applied
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TABLE 1 | Hormone regimen, study demographics, and complication rates with and without pre-operative hormonal stimulation.
Reference Study design PHS type
(delivery mode)
Dosage Schedule Time from
PHS to
surgery
Reported criteria
for PHS
Mean age
at surgery
(months)
Mean
follow-up
(months)
Complications
[no. patients/total (%)]
With PHS Without PHS
Castañón
et al. (13)
Retrospective DHT (topical) 3% Daily for 1month 1month All patients received
PHS
33 Not stated 1/6 (17) Not applicable
Koff and
Jayanthi (6)
Retrospective hCG (IM) 250 IU/dose
(pts <1 year)
2 times weekly for
5weeks
6–8weeks All patients received
PHS
10 Not stated 1/12 (8) Not applicable
500 IU/dose
(pts 1–5 years)
Lam et al. (14) Retrospective T (IM) 25mg/dose 1 dose prior to first
stage
Not stated Not stated 34 152 Not stratified Not stratified
Braga et al. (15) Retrospective T (IM) 2mg/kg/dose Not stated Not stated Subjective 17 35 Not stratified Not stratified
Braga et al. (16) Retrospective T (IM) 2mg/kg/dose 3 doses 3weeks apart Not stated Subjective 18 36 16/51 (31) 18/86 (21)
Kaya et al. (7) Randomized DHT (topical) 2.5%
(0.2–0.3mg/kg)
Daily for 3months Not stated Randomized 33 12 1/37 (3) 9/38 (24)
Catti et al. (17) Retrospective T (IM) 100mg/m2 Not stated 2months Subjective 27 30 16/26 (62) Not stratified
de Mattos e Silva
et al. (18)
Retrospective T (IM) 100mg/m2 Not stated Not stated Subjective, redo
surgery
36 24 23/36 (64) 7/16 (44)
DHT (topical) 2.50% Daily for 2months
hCG (IM) 1500 IU Every 2 days (6 doses)
Snodgrass and
Bush (19)
Retrospective T (IM) 2mg/kg/dose 3 doses every
3–4weeks
Not stated Subjective 18 12 1/8 (12.5) 2/16 (12.5)
Gorduza et al. (8) Retrospective T (IM)
hCG (IM)
T+ hCG (IM)
100mg/m2
1500 IU
1500 IU
Monthly for
2–6months
1–24months Penis length <25mm,
hypoplasia,
undescended testis
36 41 12/30 (40) 23/96 (24)
Every 2 days (6 doses)
Every 2 days (6 doses)
Rigamonti and
Castagnetti (20)
Retrospective T (IM) Not stated 2–3 times/month Not stated Not stated 16 7 1/9 (11.1) 2/5 (40)
Adapted from Wright et al. (9).
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twice daily (23). If topical DHT is used, its concentration typ-
ically ranges from 2.5 to 3% applied daily for up to 3months
(7, 18).While hCGmay be administered at 250 IU/dose in patients
younger than 1-year-old or 500 IU/dose in patients 1–5 years old,
it is typically given as 1500 IU every 2 days for a total of six doses
(6, 8, 18).
Time from PHS to Operation
When reported, the time from PHS to operation ranged from
2weeks to 24months (2, 8, 24). Some studies skipped doses if
certainmeasures were achieved such as notable increases in penile
length or glans circumference (11). It has been reported that
serum T levels return to normal range a week after being stopped
and penile growth disappears during the first year following treat-
ment (22, 24). Gorduza et al. gave monthly IM injections and
stopped when penile length was equal or >35mm (8). In their
study, boys who underwent PHS <3months prior to repair had a
non-significant higher complication rate (57%) compared to those
treated more than 3months prior (21.7%).
Adverse Effects
Reported adverse effects such as appearance of pubic hair, aggres-
sive behavior, and increased erections have been reported but are
transient and resolve post therapy (4, 6–8, 21). Kaya et al. reported
that after topical DHT, 13 of 37 boys experienced pruritus, ery-
thema, and penile pigmentation that normalized after PHS was
withdrawn (7). Koff and Jayanthi described dose-related emesis
in 1 of 12 boys receiving intramuscular T, leading to cessation of
PHS (6).Most studies report no intraoperative complications with
a focus on the absence of excess bleeding (2, 21).
In the systematic review, no persistent side effects due to PHS
were reported (9). There is some evidence that androgens can
induce delay in bone age, increase bone turnover, and increase
short-term linear height (25). However, as these concerns have not
been supported by evidence in boys with hypospadias treated with
PHS at 1-year follow-up, long-term follow-up studies are needed
to clearly address these issues (2, 4, 24).
Our Practice
In our clinical practice, the senior author uses PHS with a single
objective criterion – glans size 13mm. Increased glans size
is felt to be the single most important variable to make repair
less challenging. In a study by Bush et al., they prospectively
measured maximum glans width in boys undergoing distal and
proximal hypospadias repair, as well as newborns undergoing
elective circumcision to determine reference values for penile
dimensions (26). A boy undergoing hypospadias repair with a pre-
operative glans width of 13mm typically measured 11mm after
glans wings approximation, correlating to approximately 2 SDs
below the normal glans diameter of newborn controls (14.3mm).
Administration of PHS in boys with hypospadias with the objec-
tive criteria of13mm is though to be beneficial to increase glans
size within the normal range. Meatus location, penile hypoplasia,
and micropenis are felt to be subjective descriptors and penile
length is variable secondary to the suprapubic fat pad. Thus, we
have been administering PHS to distal, midshaft, and proximal
hypospadias and are not selecting patients for PHS subjectively.
Our treatment regimen consists of intramuscular Depo Testos-
teroneCypionate (100mg/ml) 2mg/kg up to three doses (available
in Canada). When glans size reaches the typical newborn size
of 14mm, PHS is discontinued. We discontinue PHT at least
4 weeks prior to surgery to decrease the potential risk of excessive
intraoperative bleeding secondary to tissue hypervascularitywhile
still maintaining the penile growth effects.
Conclusion
Androgen stimulation prior to hypospadias repair in some studies
has demonstrated a substantial increase in penile length, glans cir-
cumference, and tissue vascularity. However, a systematic review
suggested that PHS may be related to higher complication rates,
and treatment regimens are not standardized. Although PHS is
typically well tolerated, there is still a paucity of good data to sup-
port clinical guidelines, and well-designed prospective random-
ized placebo controlled studies are warranted to provide proof of
efficacy and further data on safety.
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